LF
ARQT icon

Lee Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Lee Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,856
Closed -$9.22K – 196
2023
Q4 		$9.22K Hold
2,856
– – ﹤0.01% 446
2023
Q3 		$15.2K Hold
2,856
– – ﹤0.01% 343
2023
Q2 		$27.2K Hold
2,856
– – ﹤0.01% 268
2023
Q1 		$31.4K Hold
2,856
– – 0.01% 266
2022
Q4 		$42.3K Hold
2,856
– – 0.01% 267
2022
Q3 		$55K Hold
2,856
– – 0.01% 242
2022
Q2 		$61K Hold
2,856
– – 0.01% 227
2022
Q1 		$55K Hold
2,856
– – 0.01% 233
2021
Q4 		$59K Hold
2,856
– – 0.01% 235
2021
Q3 		$68K Hold
2,856
– – 0.01% 203
2021
Q2 		$78K Hold
2,856
– – 0.02% 198
2021
Q1 		$83K Buy
+2,856
New +$89.2K 0.02% 188

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Lee Financial's ARQT Position: Q1 2024 in Review

Lee Financial sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 2,856 shares — an estimated $9.22K sold.

Lee Financial first reported a position in ARQT in Q1 2021 and held it in 12 quarters. The position peaked at $83K in Q1 2021. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Lee Financial reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Lee Financial sold 2,856 Arcutis Biotherapeutics shares in Q1 2024, an estimated $9.22K.
  • Lee Financial first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 12 quarters.
  • Lee Financial's Arcutis Biotherapeutics position peaked at $83K in Q1 2021.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Lee Financial's 13F filing for Q1 2024, filed 15 May 2024.